NCT07823959Not yet recruiting
CBC-Based Inflammatory Indices in Newly Diagnosed Multiple Myeloma
Association of CBC-Based Inflammatory Indices With Clinical, Laboratory, and Immunophenotypic Characteristics of Newly Diagnosed Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 17 Sept 2026
Brief summary (registry, in English)
Multiple myeloma is a type of blood cancer characterized by the abnormal growth of plasma cells in the bone marrow. Increasing evidence indicates that interactions between myeloma cells and the host immune-inflammatory response influence disease behavior and patient outcomes. Inflammatory markers calculated from routine complete blood count (CBC) tests, such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR), offer simple, inexpensive ways to assess systemic inflammation. However, how these markers correlate with baseline clinical presentation, laboratory disease burden, and tumor cell immunophenotypes remains insufficiently explored. The primary purpose of this cross-sectional study is to evaluate the association between CBC-based inflammatory indices and clinical and laboratory measures of disease severity in patients with newly diagnosed multiple myeloma prior to the start of anti-myeloma therapy. The study will also examine the relationship between these inflammatory indices and the specific immunophenotypic characteristics of neoplastic plasma cells identified via bone marrow flow cytometry. A total of 60 patients with newly diagnosed multiple myeloma presenting to Assiut University Hospital and the South Egypt Cancer Institute will be enrolled. Baseline demographic and clinical data (including CRAB manifestations and ISS/R-ISS staging), routine blood laboratory results (including albumin, beta-2 microglobulin, and LDH), bone marrow plasma cell percentages, and flow cytometric findings will be collected and analyzed.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 11 Sept 2026
- Start date
- 1 Oct 2026
- Primary completion date
- 31 Oct 2027
- Lead sponsor
- Assiut University
- Diseases
- Multiple myeloma, Childhood cancers
- NCT number
- NCT07823959
What you commit to
- Study type: Observational
- Planned participants: 60
- From 1 Oct 2026 to the primary completion date, 31 Oct 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior receipt of anti-myeloma treatment
- Concurrent active malignancies or other hematological disorders
- Concomitant use of medications that significantly alter inflammatory or hematological parameters
Other illness
- Presence of acute or chronic inflammatory or infectious conditions that may influence systemic inflammatory indices
Who the study is looking for
- Newly diagnosed Multiple Myeloma patients, evaluated prior to the initiation of anti-myeloma therapy
- Both sexes, with no age restriction
Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.